Journey Medical Corp (DERM)

Feb 5, 2025, 8:30 AM EST - 18 days ago

Stock Picks From Seeking Alpha's January 2025 New Analysts

ACIW ASML AUNA BE BITF BRAG BSY

Jan 30, 2025, 9:18 AM EST - 24 days ago

Journey Medical Corporation: Emrosi's Launch Could Be A Turning Point

Jan 23, 2025, 8:30 AM EST - 4 weeks ago

Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

FBIO

Nov 12, 2024, 4:01 PM EST - 3 months ago

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

FBIO

Nov 4, 2024, 7:00 AM EST - 3 months ago

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

FBIO

Oct 25, 2024, 8:30 AM EDT - 4 months ago

Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

FBIO

Oct 3, 2024, 8:30 AM EDT - 5 months ago

Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

FBIO

Sep 9, 2024, 8:30 AM EDT - 5 months ago

Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference

FBIO

Sep 4, 2024, 8:15 AM EDT - 6 months ago

Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

FBIO

Aug 12, 2024, 7:37 PM EDT - 6 months ago

Journey Medical Corporation (DERM) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 4:01 PM EDT - 6 months ago

Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

FBIO

Aug 6, 2024, 4:01 PM EDT - 7 months ago

Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024

FBIO

Jul 11, 2024, 4:05 PM EDT - 8 months ago

Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

FBIO

May 15, 2024, 4:01 PM EDT - 10 months ago

Journey Medical Corporation to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase

FBIO

May 13, 2024, 10:43 PM EDT - 10 months ago

Journey Medical Corporation (DERM) Q1 2024 Earnings Call Transcript

May 13, 2024, 4:01 PM EDT - 10 months ago

Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

FBIO

May 7, 2024, 8:30 AM EDT - 10 months ago

Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024

FBIO

May 1, 2024, 4:01 PM EDT - 10 months ago

Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer

FBIO

Apr 25, 2024, 8:30 AM EDT - 10 months ago

Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024

FBIO

Mar 21, 2024, 8:22 PM EDT - 1 year ago

Journey Medical Corporation (DERM) Q4 2023 Earning Call Transcript

Mar 21, 2024, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

FBIO

Mar 18, 2024, 8:30 AM EDT - 1 year ago

Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea

FBIO

Mar 15, 2024, 8:30 AM EDT - 1 year ago

Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024

FBIO

Mar 13, 2024, 8:30 AM EDT - 1 year ago

Journey Medical Corporation to Participate in the 36th Annual ROTH Conference

FBIO

Mar 11, 2024, 8:30 AM EDT - 1 year ago

Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting

FBIO

Jan 5, 2024, 8:30 AM EST - 1 year ago

Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea

FBIO

Jan 2, 2024, 4:05 PM EST - 1 year ago

Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million

FBIO

Dec 8, 2023, 4:53 PM EST - 1 year ago

The Strategic Evolution Of Journey Medical In Dermatological Care

Dec 6, 2023, 8:00 AM EST - 1 year ago

Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea

FBIO

Nov 12, 2023, 12:34 AM EST - 1 year ago

Journey Medical Corporation (DERM) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:01 PM EST - 1 year ago

Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

FBIO

Oct 31, 2023, 8:30 AM EDT - 1 year ago

Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023

FBIO

Oct 20, 2023, 8:30 AM EDT - 1 year ago

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)

FBIO

Sep 6, 2023, 8:00 AM EDT - 1 year ago

Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations

FBIO

Aug 12, 2023, 10:15 AM EDT - 1 year ago

Journey Medical Corporation (DERM) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

FBIO

Aug 2, 2023, 4:01 PM EDT - 1 year ago

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023

FBIO

Jul 19, 2023, 8:30 AM EDT - 1 year ago

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023

FBIO

Jul 11, 2023, 8:30 AM EDT - 1 year ago

Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults

FBIO

Jul 3, 2023, 8:00 AM EDT - 1 year ago

Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of Jul

FBIO

Jun 13, 2023, 8:30 AM EDT - 1 year ago

Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects

FBIO

May 22, 2023, 6:50 PM EDT - 1 year ago

Journey Medical Corp (DERM) Q1 2023 Earnings Call Transcript

May 22, 2023, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

FBIO

May 19, 2023, 4:01 PM EDT - 1 year ago

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023

FBIO

May 4, 2023, 9:00 AM EDT - 1 year ago

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023

FBIO

Mar 29, 2023, 10:13 PM EDT - 2 years ago

Journey Medical Corp (DERM) Q4 2022 Earnings Call Transcript

Mar 29, 2023, 4:01 PM EDT - 2 years ago

Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

FBIO

Mar 22, 2023, 9:00 AM EDT - 2 years ago

Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023

FBIO

Mar 16, 2023, 8:30 AM EDT - 2 years ago

Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial

FBIO

Mar 7, 2023, 8:30 AM EST - 2 years ago

Journey Medical Corporation to Participate in the 35th Annual ROTH Conference

FBIO